Breast cancer (BC) prevention in BRCA1/2 mutation carriers remains a significant clinical challenge.
Risk-reducing mastectomy (RRM) is the most effective preventive option, lowering BC incidence by over 90%.
Despite its survival benefit, the decision to undergo RRM is complex and shaped by psychological, social, and healthcare access factors.
